BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

NCT00931801 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: atazanavir/raltegravir
DRUG: atazanavir/raltegravir
DRUG: atazanavir/tenofovir/emtricitabine

Sponsor

Community Research Initiative of New England

Collaborators

[object Object]
[object Object]